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ABSTRACT 
Shikimate dehydrogenase (SDH) from Mycobacterium tuberculosis (MtbSDH), encoded 
by the aroE gene, is essential for viability of M. tuberculosis, but absent from humans. Therefore, 
it is a potentially promising target for anti-tuberculosis agent development. Molecular-level 
understanding of the interactions of MtbSDH with its 3-dehydroshikimate (DHS) substrate and 
NADPH cofactor will help in the design of novel and effective MtbSDH inhibitors. However, this 
is limited by the lack of relevant crystal structures for MtbSDH complexes. Here, molecular 
dynamics (MD) simulations were performed to generate these MtbSDH complexes, investigate 
interactions of MtbSDH with substrate and cofactor and the role of MtbSDH dynamics within 
these. The results indicate that, while structural rearrangements are not necessary for DHS binding, 
reorientation of individual side chains in the NADPH binding pocket is involved in ternary 
complex formation. The mechanistic roles for Lys69, Asp105 and Ala213 were investigated by 
generating Lys69Ala, Asp105Asn and Ala213Leu mutants in silico and investigating their 
complexes with DHS and NADPH. Our results show that Lys69 plays a dual role, in positioning 
NADPH and in catalysis. Asp105 plays a crucial role in positioning both the ε-amino group of 
Lys69 and nicotinamide ring of NADPH for MtbSDH catalysis, but makes no direct contribution 
to DHS binding. Ala213 is the selection key for NADPH binding with the nicotinamide ring in the 
proS, rather than proR, conformation in the MtbSDH complex. Our results identify three strategies 
for MtbSDH inhibition: prevention of MtbSDH binary and ternary complex formation by blocking 
DHS and NADPH binding (first and second strategies, respectively); and the prevention of 
MtbSDH complex formation with either DHS or NADPH by blocking both DHS and NADPH 
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binding (third strategy). Further, based on this third strategy, we propose guidelines for the rational 
design of “hybrid” MtbSDH inhibitors able to bind in both the substrate (DHS) and cofactor 
(NADPH) pockets, providing a new avenue of exploration in the search for anti-TB therapeutics. 
 
INTRODUCTION 
Tuberculosis (TB) remains one of the top 10 causes of death worldwide. In 2016, the WHO 
reported 6.3 million new cases of TB (up from 6.1 million in 2015).1 New patients with drug- 
susceptible TB can be cured in six months using the standard regimens, i.e. a combination of first-
line TB drugs, including isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin. 
However, Mycobacterium tuberculosis strains have developed resistance to available TB drugs. 
Drug-resistant TB is classified as multi drug-resistant tuberculosis (MDR-TB), extensively drug-
resistant tuberculosis (XDR-TB) or totally drug-resistant tuberculosis (TDR-TB).2-4 Due to drug-
resistant TB, the standard regimens using existing drugs are now often ineffective. To combat 
drug-resistant TB, intensive research efforts are being directed towards identification and 
development of new anti-TB agents. A potential strategy for the development of new drugs against 
M. tuberculosis is to target essential biosynthetic pathways of this bacterium that are absent in 
humans. This is important to facilitate design of specific anti-TB drugs with low eukaryotic 
toxicity.  
The shikimic acid pathway is present in bacteria, fungi, plants, and in certain apicomplexan 
parasites, but is absent from humans. Therefore, it is an attractive target for the development of 
new antimicrobials.5-8 Seven enzymes involved in this pathway sequentially catalyze a series of 
chemical reactions for biosynthesis, via shikimate, of chorismate from erythrose 4-phosphate and 
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phosphoenolpyruvate (Figure 1a).9 This is a precursor for the biosynthesis of aromatic amino acids, 
folate and ubiquinone, as well as vitamins E and K.7,10  
 
Figure 1. The shikimic acid pathway and Shikimate Dehydrogenase (SDH). (a) Shikimate 
pathway with reactions of the seven enzymes shown. Shikimate dehydrogenase (SDH, the fourth 
enzyme) is highlighted. (b) Structure of SDH (PDB code 3PHI). 
Shikimate dehydrogenase (SDH), encoded by the aroE gene, participates in the fourth step 
of the shikimic acid pathway. It catalyzes the reversible, NADPH-dependent, reduction of 3-
dehydroshikimate (DHS) to shikimate (SKM) (Figure 1a). The overall structure of SDH (Figure 
1b) comprises two / domains linked centrally by two -helices. A deep groove between these 
two domains contains the active site for the binding of substrate and cofactor.11-16 The crystal 
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structures of apo MtbSDH (PDB code 4P4N) and the binary SKM/MtbSDH complex (PDB code 
4P4G) have shown that it shares a common three-dimensional structure with all characterized 
members of the SDH family.11-16 Kinetic isotope effect and proton inventory studies showed that 
the kinetic mechanism of MtbSDH follows an ordered bi-bi mechanism. First, DHS binds to the 
MtbSDH active site to form the binary complex and this is followed by NADPH binding to form 
the ternary complex (Figure 2a). In the ternary complex, the C4-proS hydride (B side) of NADPH 
is transferred to DHS in the oxy-reduction reaction of MtbSDH.17 Interestingly, this differs from 
the cases of SDH enzymes from Escherichia coli (E. coli SDH) and Thermus thermophilus HB8 
(TtSDH), where the C4-proR hydride (A side) of NADPH is instead transferred.18-19 In the 
catalytic reaction of MtbSDH, both the hydride transfer from NADPH and the protonation of DHS 
proceed in the same step, a concerted mechanism (Figure 2b).17 These experiments also identified 
that an amino acid residue with an apparent pKa value of 8.9 participates in the catalytic activity 
of MtbSDH.17 Subsequently, site-directed mutagenesis showed that the conserved Lys69 plays a 
catalytic role: the kcat for wild-type MtbSDH is 68-fold larger than that of the K69A mutant.
20 SDH 
residues Lys69 and Asp105 (M. tuberculosis numbering) are conserved in TtSDH, E. coli SDH, 
Haemophilus influenzae SDH, Arabidopsis thaliana SDH-like enzyme and Methanocaldococcus 
jannaschii SDH.17,19 The crystal structures of TtSDH (PDB code 2EV9) and A. thaliana SDH-like 
enzyme (PDB code 2GPT) showed that these invariant residues are coupled by a salt bridge and 
suggest that these invariant lysine and aspartate residues form a catalytic dyad.19,21 In the absence 
of the relevant crystal structures, molecular level information on the binding modes of the DHS 
substrate and NADPH cofactor to MtbSDH remains lacking. Here, to gain insight into substrate 
and cofactor binding, binary and ternary MtbSDH complexes were modelled using in silico 
molecular dynamics (MD) simulations. Furthermore, the DHS and NADPH complex structures of 
 6 
the MtbSDH Lys69Ala (K69A), Asp105Asn (D105N) and Ala213Leu (A213L) mutants were 
modelled in silico to investigate the roles of these residues in MtbSDH mechanism. The findings 
presented here establish key interactions of substrate and cofactor with MtbSDH and identify 
mechanistic roles for MtbSDH residues. The results suggest three strategies for MtbSDH inhibition 
and provide a basis for rational design of hybrid MtbSDH inhibitors interacting with both the 





Figure 2. SDH Mechanism. (a) Kinetic mechanism of MtbSDH. Note ordered binding of DHS 
substrate and NADPH cofactor. (b) Proposed concerted catalytic mechanism for MtbSDH. 
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MATERIALS AND METHODS 
Preparation of MtbSDH complex structure  
An initial binary DHS/MtbSDH complex structure was generated by molecular docking 
calculations, as detailed below. Then, it was used to set up a ternary DHS/NADPH/MtbSDH 
complex structure. The superposition of a binary DHS/MtbSDH complex structure on the x-ray 
structure of SDH from Helicobacter pylori in complex with SKM and NADPH (PDB code 3PHI) 
was performed to generate the coordinates of NADPH in a ternary DHS/NADPH/MtbSDH 
complex structure. The nicotinamide ring of NADPH was manually rotated to the pro-S 
conformation, which changed three original torsion angles of O5B-PA-O3-PN, PN-O5D-C5D-
C4D and C2D-C1D-N1N-C2N to 1 4 7 º, -168º and 160º, respectively. A ternary DHS/proR-
NADPH/MtbSDH complex structure in which the nicotinamide ring of NADPH is in the proR 
conformation was prepared similarly to that of the DHS/NADPH/MtbSDH complex, except that 
the nicotinamide ring of NADPH was not rotated to the proS conformation. The resulting binary 
and ternary MtbSDH complex structures obtained were used as the initial coordinates for MD 
simulations and for preparing of mutant enzymes. 
Molecular docking calculations 
Molecular docking calculations were performed using the Autodock 4.2 program.22 The 
coordinates of MtbSDH from the crystal structure of the SKM/MtbSDH complex structure (PDB 
code 4P4G) were used for these calculations. Forty grid points in the x, y and z dimensions with a 
grid point spacing of 0.375 Å were used to define the 3D grid box. The grid box was centered on 
the coordinates of the SKM found in the crystal structure. With exception of the number of GA 
runs, set to 100, the default search algorithm parameters were employed, including the population 
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size (150), maximum number of energy evaluations (2,500,000), maximum number of generations 
(27,000), gene mutation rate (0.02) and crossover rate (0.80). The Kollman and Gasteiger charges 
were used for MtbSDH and small molecules (SKM and DHS), respectively. Residues of MtbSDH 
were kept rigid, whereas the structures of SKM and DHS were flexible during the molecular 
docking calculations. The number of active torsions for SKM and DHS are four and three, 
respectively. The conformations of small molecules were generated using the Lamarckian Genetic 
Algorithm (LGA) with 100 GA runs. The RMSD value between the docked and observed x-ray 
conformations of SKM smaller than 1 Å were used to verify the docking calculations. Then, 
molecular docking calculations with validated parameters were performed for DHS.  
Molecular dynamics simulations 
 MD simulations were done using AMBER16 software23 on high performance computing GPU 
hardware. All missing hydrogen atoms of MtbSDH were added using the LEaP program.24-25 The 
Amber ff12SB force field was used for MtbSDH. The general Amber force field (GAFF)26 and 
restrained electrostatic potential (RESP) partial charges27-29 of DHS and NADPH were generated 
using the Antechamber module implemented in the AMBER16 package. The initial complex 
structure was solvated with TIP3P water30 in a truncated octahedral box extending 10 Å from the 
solute species. Na+ ions were added to neutralize the system. The total number of atoms in each 
system for MD simulations was provided in Supporting Information (see Table S1). Energy 
minimization was performed in two steps, each using a steepest descent algorithm followed by a 
conjugate gradient algorithm. In the first step, water molecules and counter ions were minimized 
while restraining all atoms of the solute with a restraint weight of 500 kcal/molÅ2. In the second 
step, the whole system was minimized with no restraints. Then, the system was gradually warmed 
from 0 K to 300 K over 30 ps by restraining all atoms of the complex with a restraint weight of 2 
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kcal/molÅ2. This was followed by 70 ps of position-restrained dynamics simulation with a 
restraining weight of 2 kcal/molÅ2 at 300 K under an isobaric condition. Finally, 150 ns MD 
simulations for wild-type and mutant MtbSDH systems were performed with no restraints using 
the same conditions. Three MD simulations of each MtbSDH system were performed to assess the 
reproducibility of the results. Long-range electrostatic interactions were applied using the particle 
mesh Ewald (PME) method31 during the simulations. The cut-off distance for long-range van der 
Waals interaction was set to 8 Å. The SHAKE method32 was applied to constrain the bond lengths 
of hydrogen atoms attached to heteroatoms. Coordinates and energy outputs were recorded every 
20 ps during MD simulation. The cpptraj program33 in AMBER16 was employed to calculate the 
root mean square deviation (RMSD), root mean square fluctuations (RMSF) and distance between 
atom pairs of interest. The MM-GBSA interaction energy (see below) was calculated for snapshots 
collected every 40 ps from the equilibrium state of each system using the python script, 
MMPBSA.py34, in the AMBER16 program. The ptraj module in the AMBER12 program35 was 
used for hydrogen bond analysis and for cluster analysis of the snapshots collected from the 
equilibrium state of each system.  
Binding free energy calculation 
The binding free energy (∆Gbind) of the receptor–ligand complex was estimated from equation 4. 
The binding free energy (∆GGBSA) calculated by MM-GBSA approach using the python script 
(MMPBSA.py34) in the AMBER16 program, is the sum of the protein-ligand interaction energy 
including the electrostatic and van der Waals interaction energies (∆EMM) and the solvation free 
energy (∆Gsol) (equation 3). 1250 snapshots extracted every 40 ps from the last 50 ns of 150 ns 
MD simulations were used for calculation of ∆GGBSA. The T∆S term is the entropy contribution to 
the binding free energy, estimated using normal mode calculation with the python script 
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(MMPBSA.py34) in the AMBER12 program. Because of the high computational cost in the normal 
mode calculations, 50 snapshots extracted every 1 ns from the last 50 ns of 150 ns MD simulations 
were used to estimate the entropy contribution.    
            ∆Gbind  = ∆Ggas + ∆Gsol   (1)  
                          ∆Ggas = ∆EMM – T∆S     (2) 
   ∆GGBSA = ∆EMM + ∆Gsol   (3) 
   ∆Gbind  = ∆GGBSA – T∆S   (4) 
RESULTS AND DISCUSSION 
1. Stability of MD simulation systems  
In the absence of experimental structures, the binary DHS/MtbSDH complex structure, 
obtained from molecular docking calculations based upon the MtbSDH SKM complex structure 
(PDB code 4P4G) was used as the initial structure for MD simulations and for preparing binary 
complexes of two mutant enzymes: MtbSDH (DHS/K69A MtbSDH and DHS/D105N MtbSDH). 
In the initial structure for MD simulations of the ternary DHS/NADPH/MtbSDH complex, the 
coordinates of NADPH and DHS were generated by superposition and molecular docking 
calculations, respectively. The RMSD of DHS, NADPH and MtbSDH with respect to their initial 
structures was then calculated over the duration of MD simulations to reveal the system stability. 
Three wild-type systems (apo MtbSDH, binary DHS/MtbSDH and ternary 
DHS/NADPH/MtbSDH) were equilibrated for 20 ns, 50 ns and 5 ns, respectively, and 
subsequently remained stable over the rest of the simulation time (150 ns per simulation as 
described in Methods) for three MD simulations of each system (see Supporting Information 
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Figure S1). These indicated that wild-type MtbSDH readily reached an equilibrium state when 
bound to both of DHS substrate and NADPH cofactor. The mutant systems (DHS/K69A MtbSDH, 
DHS/D105N MtbSDH, DHS/NADPH/K69A MtbSDH and DHS/NADPH/D105N MtbSDH) 
reached the equilibrium state after 20 ns, 50 ns, 20 ns and 80 ns, respectively (see Supporting 
Information Figures S2 and S3). Simulations of ternary complexes of wild-type MtbSDH and the 
A213L mutant, in which the nicotinamide ring of NADPH is in the proR conformation 
(DHS/proR-NADPH/MtbSDH and DHS/proR NADPH/A213L MtbSDH, respectively), reached 
the equilibrium state after 90 ns and 40 ns, respectively (see Supporting Information Figure S4). 
A representative snapshot of the most populated cluster obtained from cluster analysis was selected 
as the representative structure for each MD simulation (see Supporting Information Table S2). 
Three representative structures obtained from three MD simulations of each system differed only 
slightly: across all nine systems tested average RMSD values from pairwise comparisons of 
replicate simulations were in the range of 1.07-1.44 Å, indicating the reproducibility of the results 
(see Supporting Information Table S3). Therefore, for each MtbSDH system one of these three 
representative structures with the highest percent occurrence was selected as the representative 
structure for that system and used for structural analysis and comparison (see Supporting 
Information Table S2).  
2. Overall structure of MtbSDH 
The DHS/NADPH/MtbSDH complex structure modeled here superposes well with the 
crystal structure of SKM/NADPH/H. pylori SDH (Figure 3a). The DHS and SKM substrate found 
in these structures are positioned in the same pocket and this is observed for NADPH. A deep 
groove created between N-terminal and C-terminal domains linked centrally by two -helices is 
the active site for the binding of DHS substrate and NADPH cofactor (Figure 3b). The binding 
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residues of DHS and NADPH were defined from DHS/NADPH/MtbSDH complex within the 
radius of 4 Å from DHS and NADPH. The DHS binding residues are residues 17-20, 63-66, 90 
and 247 and those for NADPH are residues 124-129, 149, 153, 191-193, 196, 213, 236, and 239. 
Residues 69, 105, 215, 240 and 243 participated in binding of both DHS and NADPH. Residues 
124-129 form the diphosphate-binding loop which is conserved in the SDH family19.  
  
Figure 3. Model of DHS/NADPH/MtbSDH ternary complex. (a) superposition of representative 
structure of the DHS/NADPH/MtbSDH complex modeled by MD simulation (blue) and the crystal 
structure of SKM/NADPH/H. pylori SDH (PDB code 3PHI, gray). Carbon atoms of DHS/NADPH 
and SKM/NADPH are colored yellow and gray, respectively. (b) DHS/NADPH/MtbSDH ternary 
complex structure obtained from MD simulations. N-terminal (residues 5-103 and 254-269) and 
C-terminal (residues 114-235) domains are shown in yellow and purple, respectively. Two -
helical interdomain linkers (residues 104-113 and 236-253) are shown in pink. Colored residues 
bind DHS (orange), NADPH (blue) or both DHS and NADPH (red); diphosphate-binding loop is 
colored green.   
 
3. Flexibility of MtbSDH 
 Successful generation of stable models for MtbSDH and its complexes prompted 
investigation of enzyme flexibility and the effect upon it of ligand binding and mutation. RMSF 
values for MtbSDH were calculated from the MD simulations to visualize the flexibility of apo, 
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ligand-bound and mutant MtbSDHs. RMSF values for ligand-unbound MtbSDH (apo MtbSDH) 
and ligand-bound MtbSDH (DHS/MtbSDH and DHS/NADPH/MtbSDH) were compared to reveal 
the influence of ligand binding on the flexibility of MtbSDH. Standard deviations of RMSF values 
for each MtbSDH residue in these different complexes were calculated to show the difference of 
their flexibilities. RMSF values of MtbSDH residues in apo MtbSDH, DHS/MtbSDH and 
DHS/NADPH/MtbSDH were in the range ~2 – 12 Å (Figure S5a). For residues binding either 
DHS or NADPH as defined above, RMSF values were in the ranges ~2 – 6 Å and ~2 – 7 Å, 
respectively. The standard deviations of RMSF values for each residue in ligand-unbound and 
ligand-bound MtbSDHs were in the range ~ 0 – 1 Å (Figure S5a). These data indicate that binding 
of DHS substrate and NADPH cofactor do not affect the flexibility of MtbSDH. RMSF values of 
binary complexes of wild-type (DHS/MtbSDH) and mutant (DHS/K69A MtbSDH and 
DHS/D105N MtbSDH) MtbSDH were then compared to reveal the influence of these mutations 
on flexibility. RMSF value of MtbSDH residues in these complexes were in the range ~2 – 15 Å 
(Figure S5b). Standard deviations of RMSF values of each residue in wild-type and mutant 
MtbSDH were in the range ~ 0 – 3 Å (Figure S5b). This indicates that the K69A and D105N 
mutations have greater effects on the flexibility of MtbSDH compared to those of ligand binding. 
However, these mutations showed only a small influence on the flexibility of the DHS and NADPH 
binding residues, with standard deviation values for these positions in the range ~ 0 – 1 Å (Figure 
S5b).     
4. Structural rearrangement of MtbSDH for DHS and NADPH binding 
 The conformational change of MtbSDH upon DHS binding was investigated by calculating 
RMSD values between atoms of apo MtbSDH (PDB code 4P4N) and those of the representative 
structure for the binary DHS/MtbSDH complex obtained from MD simulations. The backbone 
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atoms of MtbSDH in the binary DHS/MtbSDH complex superpose well with those of apo MtbSDH 
as indicated by the small overall RMSD value of 1.35 Å. In the DHS binding pocket, RMSD values 
of all heavy atoms (backbone and sidechain atoms) of binding residues were in range of 0.5 – 2.5 
Å. This indicates that the conformations of the DHS binding residues were not significantly 
changed upon DHS binding. The exception, His17, had the highest RMSD value (5.2 Å) as His17 
changes conformation to interact, via a hydrogen bond, with the carboxylate moiety of DHS 
(Figure 4a). On the other hand, residues Lys69 and Asp105, that are conserved in other SDHs and 
are coupled by a salt bridge17,19 showed insignificant positional changes on DHS binding, with 
small RMSD values of 1.0 and 0.5 Å (Figure 4a), respectively. These data suggest that DHS 
binding by MtbSDH does not require extensive structural rearrangement. The binding 
conformation of DHS in the DHS/MtbSDH complex structure obtained after MD simulation was 
also very similar to that of shikimate (SKM) found in the crystal structure of MtbSDH (PDB code 
4P4G; Figure S6). However, compared to the SKM complex, the active site residues significantly 
rearrange on DHS binding. This rearrangement might result from replacement of the C5 hydroxyl 
group of SKM with a carbonyl oxygen in DHS. The carbonyl oxygen in DHS moved down as 
compared to the position of hydroxyl group of SKM. This causes the ε amino group (-NH3
+) of 
Lys69 moved to the carbonyl oxygen of DHS, inducing repositioning of Asp105 and other residues 
(Figure S6). 
The conformational change of MtbSDH upon NADPH binding was also investigated. 
Superposition of all backbone atoms in the binary DHS/MtbSDH and ternary 
DHS/NADPH/MtbSDH complexes obtained from MD simulations showed a small RMSD value 
of 1.37 Å. In the NADPH binding pocket, RMSD values of all heavy atoms (backbone and 
sidechain atoms) of NADPH binding residues were in range of 0.5 – 9.9 Å. Residues Lys69 and 
 15 
Asp105 remained coupled by a salt bridge and showed insignificant positional change on NADPH 
binding as evidenced by RMSD values of 1.1 Å and 0.5 Å, respectively (Figure 4b). In the 
diphosphate-binding loop (residues 124-129), there are no large structural changes associated with 
NADPH binding, as indicated by RMSD values in the range of 1.6 - 3.6 Å. However, two charged 
residues, Arg149 and Lys153, do undergo significant conformational changes upon NADPH 
binding, with high RMSD values of 9.9 Å and 6.6 Å, respectively. These large conformational 
changes of Arg149 and Lys153 are responsible for creating an ‘electrostatic clamp’19 to bind the 
adenine phosphate of NADPH in the DHS/NADPH/MtbSDH complex (Figure 4b). Thus, MtbSDH 
requires only specific, highly local, structural rearrangements for NADPH binding. However, 
NADPH binding does induce positional changes of the DHS substrate and Tyr215 with RMSD 
values compared to the DHS/MtbSDH binary complex of 2.59 Å and 3.3 Å, respectively. In the 
ternary complex the DHS substrate lies close to the nicotinamide ring of NADPH and the side 
chain of Tyr215 interacts with the carboxylate group of DHS (Figure 4b). The remaining residues 
involved in DHS binding underwent no significant conformational changes on NADPH binding, 




Figure 4. DHS and NADPH binding by MtbSDH. (a) superposition of DHS binding residues in 
apo MtbSDH (PDB code 4P4N, carbon atoms gray) and binary DHS/MtbSDH complex obtained 
from MD simulations (carbon atoms green). (b) superposition of NADPH binding residues in 
binary DHS/MtbSDH (carbon atoms green) and ternary DHS/NADPH/MtbSDH (carbon atoms 
pink) complexes obtained from MD simulations. Black dotted arrows indicate the direction of 
movement of each residue on NADPH binding. (c) and (d), plots of MM-GBSA decomposition 
energy showing contribution of each MtbSDH residue to DHS binding in the binary DHS/MtbSDH 
complex and to NADPH binding in the ternary DHS/NADPH/MtbSDH complex, respectively. 
5. DHS binding in the binary DHS/MtbSDH complex 
In the SKM/MtbSDH crystal structure, SKM forms numerous hydrogen bonds to Ser18, 
Ser20, Thr65, Lys69, Asn90, Asp105, Tyr215, Gln243 and Gln247. Therefore, hydrogen bond 
analysis over the equilibrium state of MD simulations was performed for DHS binding in the 
representative structure for the binary DHS/MtbSDH complex structure. Excepting hydrogen 
bonds formed by Asn90, Asp105 and Tyr215, all hydrogen bonds involved in SKM binding were 
retained for DHS binding (Figure S7a). Additional hydrogen bonds to His17, Ser63 and Val64 
were formed for DHS binding. The percent occupation of all hydrogen bonds involved in DHS 
binding (i.e. the number of frames in which each hydrogen bond is considered to form over the 
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total number of frames selected for hydrogen bond analysis) was in the range of 28 - 100. Notably, 
hydrogen bonds formed by Ser18, Val64, Lys69, Thr65 and Gln247 showed higher percent 
occupation (91 - 100) than others. In particular, Ser18 invariably formed a hydrogen bond to DHS 
(100% occupied) (Figure S7a). The contributions of these hydrogen bonds, as well as other 
interactions, to DHS binding were further evaluated by their decomposition energies (Figure 4c). 
The most prominent contributions to DHS binding in MtbSDH, as evidenced by their lower 
decomposition energies, were made by residues Ser18, Thr65, Lys69, Gln243 and Gln247 forming 
hydrogen bonds to DHS. These data indicate that hydrogen bonds are the main interaction for DHS 
binding in MtbSDH. Remarkably, only Asp105 shows a significant positive decomposition energy 
(~2 kcal/mol) with respect to DHS in the DHS/MtbSDH binary complex (Figure 4c), indicating 
that this residue makes no contribution to DHS binding in this complex. 
6. DHS and NADPH binding in the ternary DHS/NADPH/MtbSDH complex 
Models for MtbSDH complexes after MD simulations were next considered with respect 
to the proposed catalytic mechanism (Figure 2b). Importantly, the positions of DHS and NADPH 
in the ternary (DHS/NADPH/MtbSDH) complex obtained after MD simulations are consistent 
with a concerted mechanism. The DHS substrate is located close to the nicotinamide ring of 
NADPH in the proS conformation (Figure 5a). The trajectory of distance between the proS 
hydrogen of NADPH and the C5 atom of DHS over 150 ns MD simulations was shown in Figure 
S8. The average of this distance over the equilibrium state was 4.18 ± 0.40 Å. This is consistent 
with a proS hydride transfer from NADPH to the C5 atom of DHS in the oxy-reduction reaction 
catalyzed by MtbSDH (Figure 2b).17 The NH3
+ of Lys69 and the C5 carbonyl oxygen of DHS are 
separated by a distance of 2.86±0.17 Å (Figure 5a), which is consistent with proton transfer 
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between them. The negatively charged groups of Asp105 and NADPH sandwich the NH3
+ of 
Lys69 (Figure 5a), which may serve to facilitate proton transfer. 
  The electrostatic clamp created by Arg149 and Lys153 interacts with the adenine 
phosphate of NADPH via hydrogen bonds (80-97% occupation) (Figure S7b). This electrostatic 
clamp showed the highest contribution to NADPH binding in MtbSDH as indicated by the lowest 
decomposition energy (Figure 4d). The pyrophosphate of NADPH interacts with the diphosphate-
binding loop (residues Gly124 - Ala129, forming hydrogen bonds with Ser125, Gly126, Gly127 
and Thr128 (Figure S7b). Hydrogen bonds formed by the diphosphate-binding loop are very 
similar to those found in the NADP+ binding sites of SDH from E. coli and T. thermophilus HB8 
(PDB codes 1NYT and 2EV9, respectively). In addition, Lys69, Asp105 and Gln243 found in the 
DHS binding pocket formed hydrogen bonds (97-100 % occupied) with NADPH (Figure S7b).   
 
Figure 5. MtbSDH Utilizes NADPH in the proS form. (a) NADPH and DHS binding in 
representative structure of the ternary DHS/NADPH/MtbSDH complex derived from MD 
simulations. NADPH and DHS binding shows proposed route of hydride transfer and interactions 
of Lys69 and Asp105 with NADPH and DHS. Dotted lines indicate interaction, red dotted arrow 
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indicates the direction of proS hydride transfer. (b) binding of NADPH in the proR form to wild-
type and A213L MtbSDH. NADPH and DHS binding in representative structures of the 
DHS/proR-NADPH/MtbSDH (cyan) and DHS/proR NADPH/A213L MtbSDH (yellow) ternary 
complexes. The catalytic pocket, electrostatic clamp (Arg149 and Lys153) and site of the 
Ala213Leu mutation are highlighted in orange dotted circle, green and pink, respectively.  
7. Selection of proS conformation of NADPH nicotinamide ring  
The oxy-reduction reaction of MtbSDH occurs by transfer of the C4-proS hydride (B face) 
of NADPH to DHS (Figure 2b).17 This differs from the cases of SDH enzymes from H. pylori, E. 
coli and TtSDH, where the C4-proR hydride (A face) of NADPH is instead transferred.18-19 Hence 
MD simulations of a ternary DHS/NADPH/MtbSDH complex structure in which the nicotinamide 
ring of NADPH is in the proR conformation (DHS/proR-NADPH/MtbSDH) were undertaken to 
investigate why proR hydride transfer is not favored for MtbSDH. 150 ns MD simulations of the 
DHS/proR-NADPH/MtbSDH ternary complex showed that in the proR conformation the 
nicotinamide ring of NADPH did not remain in the catalytic pocket of MtbSDH, responsible for 
binding the DHS substrate and NADPH nicotinamide ring, although NADPH remained bound to 
MtbSDH due to retention of interactions with the electrostatic clamp (Figure 5b). These data 
indicate that MtbSDH is unable to bind NADPH in the proR conformation in an orientation 
competent for hydride transfer. 
To further investigate why MtbSDH does not favor binding of the nicotinamide ring of 
NADPH in the proR conformation, the respective NADPH binding pockets for MtbSDH and H. 
pylori SDH were compared (Figure S9). The conformations of Lys69, Gly236, Met239 (MtbSDH 
numbering) in both enzymes are similar. In H. pylori SDH, the proR nicotinamide ring of NADPH 
 20 
forms a hydrogen bond to the invariant glycine (Gly230) and interacts with the two hydrophobic 
sidechains of Leu208 and Met233. However, in MtbSDH the smaller sidechain of Ala213 replaces 
the alkyl hydrophobic sidechain of Leu208 in H. pylori SDH, suggesting that the differing 
sidechains of Leu208 and Ala213 respectively select for the proR and proS forms of the NADPH 
nicotinamide ring. To test this hypothesis, MD simulations of a ternary DHS/proR-
NADPH/MtbSDH structure containing the Ala213Leu (A213L) mutant (DHS/proR 
NADPH/A213L MtbSDH) were performed. MD simulations showed that proR NADPH in the 
A213L mutant complex readily reached an equilibrium state (~5 ns), whereas this in the wild-type 
complex difficultly reached an equilibrium state (~90 ns), (see Supporting Information Figure S4). 
In contrast to the wild-type enzyme, the proR nicotinamide ring of NADPH remains bound in the 
catalytic pocket of the A213L MtbSDH mutant (Figure 5b). Accordingly, we conclude that in 
MtbSDH the sidechain of Ala213 selects for the proS form of the NADPH nicotinamide ring 
toward to the proS hydride transfer favoured for MtbSDH.   
8. Roles of Lys69 and Asp105 in the reaction of MtbSDH 
The role of Lys69 in the catalytic mechanism of MtbSDH has been investigated 
experimentally. Steady-state kinetic measurements showed that the turnover number (kcat) for 
wild-type MtbSDH (50 s-1) is 68-fold greater than that for the K69A mutant (0.73 s-1), indicating 
a critical role in catalysis for Lys69, probably in proton transfer to the C5 carbonyl of DHS.20 In 
MtbSDH Lys69 and Asp105 are coupled by a salt bridge (Figure 6a), suggesting that Asp105 may 
also have a mechanistic function, possibly by affecting either the flexibility of Lys69 or the 
distance between Lys69 and DHS during the catalytic reaction. Therefore, we modelled the D105N 
mutant in complex with DHS (DHS/D105N MtbSDH complex) to investigate the role of Asp105 
in the catalytic function of MtbSDH. Specifically, the distance between the C5 carbonyl oxygen 
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atom of DHS and the ε amino nitrogen atom (-NH3
+) of Lys69 was measured over the equilibrium 
state of MD simulations for DHS/MtbSDH and DHS/D105N MtbSDH binary complexes (Note 
that, as described above, the mutation exerted only limited effects on the global dynamics of 
MtbSDH). In the simulation of the DHS/MtbSDH complex, the average distance between the DHS 
C5 carbonyl oxygen and the Lys69 ε amino nitrogen atom was 2.89±0.34 Å (Figure 6a), close to 
that observed (2.94 Å) for the Lys69 ε amino nitrogen and the C5 hydroxyl oxygen of SKM in the 
crystal structure of the SKM/MtbSDH complex (PDB 4P4G). For the D105N mutant this average 
distance was 5.22±2.06 Å (Figure 6b), almost double that found in wild-type MtbSDH, indicating 
that proton transfer to C5 is hampered in the D105N mutant MtbSDH. Moreover, the ε amino 
nitrogen atom of Lys69 in the D105N mutant MtbSDH was much more mobile than in wild-type 
MtbSDH (Figures 6a and 6b). Accordingly, our simulations suggest that Asp105 plays a crucial 
rule in fixing the ε-amino group of Lys69, via a salt bridge, in a suitable position to participate in 
the catalytic reaction of MtbSDH. In support of this conclusion, the D423N mutant of the A. 
thaliana SDH-like enzyme, (equivalent to the D105N mutant of MtbSDH), showed substantial 
reduction in kcat values from 428 s
–1 (wild-type) to 0.121 s–1, (D423N mutant).21 Thus mutation of 
Asp105 would be expected to decrease the catalytic activity of MtbSDH.  
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Figure 6. Effects of mutations at MtbSDH Lys69 and Asp105. Motion of Lys69 in (a) wild-
type and (b) D105N MtbSDH. Figure shows distances between the DHS C5 carbonyl oxygen and 
Lys69 ε amino nitrogen atom averaged over the equilibrium state of each simulations for 
representative structures generated by cluster analysis after MD simulations of DHS complexes. 
(c) Effect of K69A and (d) effect of D105N mutations on DHS binding. Superpositions of DHS in 
representative structures obtained after MD simulations for wild-type (DHS carbon atoms blue) 
and mutant (DHS carbon atoms yellow) MtbSDH binary complexes. Carbon atoms of identified 
residues in wild-type and mutant MtbSDH are green and pink, respectively. Red dotted lines 
indicate hydrogen bonds formed by MtbSDH mutants. 
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9. Roles of Lys69 and Asp105 in DHS and NADPH binding by MtbSDH 
In the binary complex of DHS and MtbSDH, Lys69 showed stronger interaction energies 
than other residues (Figure 4c), indicating a greater contribution to DHS binding. Moreover, it 
formed persistent hydrogen bonds to DHS, with 92% occupancies over the equilibrium state of 
MD simulations (Figure S7a). However, experiments indicate that Lys69 plays only a minor role 
in DHS binding, as evidenced by comparison of KM values for DHS in wild-type and K69A mutant 
MtbSDH of 29 and 76 µM, respectively.20 Similarly, Asp105 showed a positive decomposition 
energy (~2 kcal/mol) for DHS binding in the binary MtbSDH complex, and did not form hydrogen 
bonds with DHS (Figures 4c and S7a). In the A. thaliana SDH-like enzyme, mutation of Asp423, 
equivalent to Asp105 in MtbSDH, to Asn (D423N) does not affect the binding affinity for 
shikimate as indicated by KM values for wild-type enzyme and the D423N mutant of 685 and 555 
µM, respectively.21 Given the apparent discrepancy between these data and the results of our 
decomposition analysis, we sought to investigate the possible role of residues 69 and 105 in DHS 
binding using MD simulations of binary DHS complexes of K69A and D105N MtbSDH 
(DHS/K69A MtbSDH and DHS/D105N MtbSDH, respectively). Our results showed that the 
K69A and D105N mutants did not significantly change the binding free energies of DHS in 
MtbSDH, as evidenced by the calculated binding free energies for DHS in wild-type, K69A and 
D105N mutant MtbSDH (-33.6, -29.5 and -34.3 kcal/mol, respectively, Table 1). 
However, the K69A mutation significantly changes the binding position of DHS as 
compared to that in wild-type MtbSDH (Figure 6c). The carboxylate group of DHS moves closer 
to Arg19 and Ser20, resulting in formation of three hydrogen bonds and an additional interaction 
with Ser18. These interactions showed negative decomposition energies in the range ~4-6 
kcal/mol, lower than other residues (~0-2 kcal/mol) (see Supporting Information Figures S10a). 
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Furthermore, the DHS C4 hydroxyl group is held in place by a hydrogen bond to Asp105 (Figure 
6c) with a negative decomposition energy ~2 kcal/mol. Remarkably, Asp105 shows a significant 
positive decomposition energy (~2 kcal/mol) with respect to DHS binding to wild-type MtbSDH 
(Figure 4c). These results indicate that Asp105 contributes to DHS binding in the MtbSDH K69A 
mutant. Thus, additional hydrogen bonds formed between DHS, Arg19, Ser20 and Asp105 in 
K69A MtbSDH may compensate for the loss of interactions involving Lys69 in the wild-type 
enzyme, and may help to maintain kM values for DHS at the same level. 
In D105N MtbSDH, the binding position of DHS changes only slightly as compared to that 
in the wild-type enzyme (Figure 6d), and the decomposition energy patterns of DHS binding in 
wild-type and mutant D105N MtbSDH are similar (Figures 4c and S10b, respectively). The most 
prominent contributions to DHS binding in D105N MtbSDH, involve hydrogen bonds formed by 
residues Ser18 and Thr65, as evidenced by their lower negative decomposition energies (~5 
kcal/mol). Further, DHS formed an additional hydrogen bond to the mutated residue Asn105, also 
with a negative decomposition energy (~3 kcal/mol). These additional interactions compensate for 
the loss of the salt bridge created between Lys69 and Asp105 in wild-type MtbSDH (see above) 
with consequent loss of a hydrogen bond between DHS and Lys69. Our analysis however indicates 
that, consistent with experimental data from the A. thalania system, in wild-type MtbSDH, Asp105 





Table 1. The calculated binding free energies (Gbind) of DHS in wild-type, K69A and D105N 
mutant MtbSDH complexes (DHS/MtbSDH, DHS/K69A MtbSDH, DHS/D105N MtbSDH).  
System aGGBSA –TSa aGbind 
DHS/MtbSDH –18.4±3.9b –15.2±2.2 b –33.6±2.7 b 
DHS/K69A MtbSDH –13.4±5.3 –16.1±1.1 –29.5±6.3 
DHS/D105N MtbSDH –17.3±3.7 –17.0±0.7 –34.3±3.7 
  aThe value was averaged from three MD simulations of each complex. 
  bThe standard deviation value (sd) of each term obtained from three MD simulations. 
    
Decomposition analysis of interaction energies for NADPH binding in the ternary 
DHS/NADPH/MtbSDH complex (see above) identifies the electrostatic clamp created by Arg149 
and Lys153 as making the greatest contribution to NADPH binding by MtbSDH (Figure 4d), 
consistent with investigations of SDHs from E. coli and T. thermophilus HB8 that support a crucial 
role for the electrostatic clamp in binding the adenine phosphate of NADP. 13,19 However, after the 
electrostatic clamp, Lys69 shows the lowest decomposition energy for NADPH binding, and forms 
a hydrogen bond to NADPH at 97% occupation over the equilibrium state of MD simulations 
(Figures 4d and S7b). Furthermore, although Asp105 showed a positive decomposition energy (~2 
kcal/mol) for DHS binding in the binary complex (Figure 4c), it had a negative decomposition 
energy (~1 kcal/mol) for NADPH binding in the ternary complex (Figure 4d) and formed a 
hydrogen bond (98% occupation) with NADPH (Figure S7b). Thus, both Lys69 and Asp105 may 
be important in NADPH binding by MtbSDH. Accordingly, ternary complexes of the K69A and 
D105N mutants (DHS/NADPH/K69A and DHS/NADPH/D105N MtbSDH) were simulated in 
order to investigate the roles of these residues in NADPH binding. For both mutations, NADPH 
remained bound in simulations of the respective ternary (DHS/NADPH/MtbSDH) complexes, but, 
compared to the wild-type complex, in neither case was the proS nicotinamide ring of NADPH 
located in a suitable position to participate in the catalytic reaction (Figure 7) and in both mutants 
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NADPH is more mobile than in the wild-type enzyme (see Supporting Information Figures S3 and 
S1c, respectively). Our simulations show that both Lys69 and Asp105 have dual roles in MtbSDH, 
being involved in the catalytic reaction and in positioning the proS nicotinamide ring of NADPH 
for catalysis. 
 
Figure 7. NADPH and DHS binding to ternary MtbSDH complexes. Models of (a) wild-type, 
(b) K69A and (c) D105N MtbSDH ternary complexes. Models shown are representative structures 
obtained after MD simulations as described above. DHS carbon atoms are shown in cyan; NADPH 
carbons in gray. 
DISCUSSION 
 
Strategy for MtbSDH inhibition 
Binary and ternary complexes of MtbSDH with DHS substrate and NADPH cofactor 
modelled here by MD simulations provide molecular-level understanding of the interactions and 
structural rearrangement of MtbSDH for binding its substrate and cofactor. Combining information 
from these models of the MtbSDH complexes with proposed catalytic mechanisms of MtbSDH 
allows us to propose three possible strategies for MtbSDH inhibition by small molecules. The first 
strategy is prevention of binary complex formation in the first step of MtbSDH catalysis (Figure 
2a) by competitive inhibition by small molecules with respect to the DHS substrate, i.e. DHS-
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competitive inhibitors that resemble the substrate and bind to the DHS binding pocket. The DHS 
binding pocket does not require structural rearrangement for substrate binding, as evidenced by 
comparison of RMSD values for simulations of apo and DHS-bound MtbSDH. Therefore, the size 
and shape of DHS-competitive inhibitors should mimic those of the DHS substrate. Further, our 
decomposition analysis shows that Lys69 and Ser18 make the largest contributions to DHS 
binding, forming hydrogen bonds to the DHS C5 carbonyl and carboxylate oxygen atoms, 
respectively. Small molecules able to form hydrogen bonds with these residues would thus be 
promising DHS-competitive inhibitors. 
The second inhibition strategy is blocking of NADPH binding in the second step of 
MtbSDH catalysis (Figure 2a), i.e. preventing formation of the MtbSDH ternary complex. Our 
simulations show that in MtbSDH the electrostatic clamp created by Arg149 and Lys153 shows 
the strongest interaction for NADPH binding with high negative decomposition energies (~30 
kcal/mol) (Figure 4d). However, Arg149 and Lys153 require specific structural rearrangements to 
create the electrostatic clamp, as detailed in the previous section, making it difficult for small 
molecules to bind competitively in this site. Alternatively, small molecules able to bind in the 
binding pocket of the nicotinamide ring of NADPH might present a more promising strategy. In 
this pocket, the NADPH proS nicotinamide ring forms hydrogen bonds to Asp105, Thr128 and 
Gln243 with % occupations in the range of 73 – 100% (Figure S7b). Moreover, this moiety 
interacts with the hydrophobic side chain of Ala213, proposed here to be important as the basis for 
selection of the proS conformation of the nicotinamide ring, as well as with the hydrophobic side 
chains of Thr128, Thr191 and Met239 (Figure 8a). Therefore, small molecules bearing both 
hydrophobic and hydrophilic moieties, thus enabling hydrophobic interactions with Thr128, 
Thr191, Ala213 and Met239 and hydrogen bonds to Asp105, Thr128 and Gln243, would be 
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expected to bind in the nicotinamide ring binding pocket and act competitively with respect to 
NADPH. 
A final strategy for MtbSDH inhibition is the prevention of both DHS and NADPH binding. 
Small molecules utilising the binding pockets for both DHS and the NADPH nicotinamide ring 
would be required to implement this strategy, and would be expected to act as competitive 
inhibitors with respect to both DHS substrate and NADPH cofactor. A combination of structural 
features of small molecules identified using the first and second strategies would be required for 
this type of competitive inhibitor. In other systems, approaches targeting two substrate-binding 
sites of a single enzyme successfully identified an inhibitor with low nanomolar potency.36 
Therefore, we propose MtbSDH inhibitors targeting the binding pockets of both DHS and of the 
proS nicotinamide ring of NADPH and term these hybrid inhibitors (Figure 8b). Head and tail 
groups would follow those of compounds identified using the first and second inhibition strategies, 
with the tail of the hybrid inhibitor attached to the head group via a linker equivalently positioned 
to a location between the C5 carbonyl and carboxylate oxygen atoms of DHS, in order to facilitate 
binding in the nicotinamide ring pocket (Figure 8b). Furthermore, as hydrophilic agents only 
slowly cross the mycobacterial cell wall,37 hydrophilic moieties in the tail would be removed in 
order to balance the hydrophilicity of hybrid inhibitors arising from the likely presence of 
negatively charged carboxylate groups at the head. As growing evidence indicates that presence 
of negatively charged carboxylate groups on small molecule compounds decreases activity against 
M. tuberculosis,39 our preferred strategy would be to administer such compounds as lipophilic 
prodrugs, hypothesizing that such compounds would be slowly hydrolyzed to the active 
(carboxylate) form after absorption by M. tuberculosis. This strategy has successfully improved 
MIC values for anti-TB agents, with propyl ester prodrugs providing the most efficient in vitro 
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activities against M. tuberculosis.38 Therefore, hybrid inhibitors in the form of propyl ester 




Figure 8. Rationale for hybrid MtbSDH inhibitors. (a) Interactions of the NADPH nicotinamide 
ring in representative structure of the ternary MtbSDH complex. (b) Proposed scaffold for hybrid 
inhibitors based on the binding of DHS substrate and NADPH nicotinamide ring as identified in 
simulations of the ternary DHS/NADPH/MtbSDH complex. 
CONCLUSIONS 
Models of the binary DHS/MtbSDH and ternary DHS/NADPH/MtbSDH complexes, 
together with the apoenzyme, were generated and investigated using docking and MD simulations. 
Complexes of MtbSDH mutants were also modelled to investigate the roles of Lys69 and Asp105 
in binding and/or catalysis and the role of Ala213 in the stereospecific selection of the nicotinamide 
ring of NADPH. The results show that Lys69 plays a dual role, crucial for catalysis (proton transfer 
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to the C5 carbonyl of DHS) and for positioning the nicotinamide ring of NADPH for catalysis. 
Asp105 holds both the ε-amino group of Lys69 and the nicotinamide ring of NADPH in suitable 
positions to participate in the catalytic reaction of MtbSDH. However, it made no contribution to 
DHS binding in the binary MtbSDH complex. Furthermore, our work identifies the sidechain of 
Ala213 as the selection key for the proS conformation of the NADPH nicotinamide ring of 
NADPH, differentiating MtbSDH from related enzymes that instead utilize the proR form. Finally, 
integration of the information obtained from this work provides three potential strategies for 
MtbSDH inhibition, and allows us to propose the skeleton of a hybrid inhibitor able to utilize both 
the DHS and NADPH pockets to bind MtbSDH. Future experiments will test this hypothesis. 
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